International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

Actions
  • Price (GBX)686.00
  • Today's Change8.00 / 1.18%
  • Shares traded144.47k
  • 1 Year change+18.69%
  • Beta0.1786
Data delayed at least 15 minutes, as of Nov 22 2024 16:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Aug 31 2024202420232022
ASSETS
Cash And Short Term Investments10--0
Total Receivables, Net0.212.9313
Total Inventory------
Prepaid expenses0.010.040.07
Other current assets, total------
Total current assets112.9713
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments298302313
Note receivable - long term------
Other long term assets------
Total assets308305327
LIABILITIES
Accounts payable------
Accrued expenses1.191.190.86
Notes payable/short-term debt233240
Current portion long-term debt/capital leases------
Other current liabilities, total1.870.891.20
Total current liabilities263542
Total long term debt000
Total debt233240
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities263542
SHAREHOLDERS EQUITY
Common stock101010
Additional paid-in capital303030
Retained earnings (accumulated deficit)242230245
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity282270285
Total liabilities & shareholders' equity308305327
Total common shares outstanding373941
Treasury shares - common primary issue4.552.070.52
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.